Physician profile
Brian Mark Solinsky
NPI 1598320798
$2,084.17
in general payments reported to CMS, 2019-2025
19 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.47 · 2023: $71.20 · 2024: $542 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.51 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $384.98 | 2024-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $259.54 | 2022-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Rxsight INC | $178.95 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Regeneron Healthcare Solutions, INC. | $119.84 | 2024 | Eylea Hd |
| Dompe US, INC. | $95.17 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $94.08 | 2025 | Xdemvy |
| Alimera Sciences, INC. | $92.00 | 2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $62.53 | 2023-2024 | Vabysmo |
| Oyster Point Pharma, INC. | $54.92 | 2022-2025 | Ryzumvi, Tyrvaya |
| Apellis Pharmaceuticals, INC. | $46.79 | 2025 | Syfovre |
| Harrow Eye, LLC | $46.22 | 2024 | Vevye |
| Ocular Therapeutix, INC. | $42.29 | 2025 | Dextenza |
| Eyepoint US, INC. | $39.18 | 2023 | |
| Astellas Pharma US INC | $34.21 | 2025 | Izervay |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $29.32 | 2024 | |
| Sun Pharmaceutical Industries INC. | $26.54 | 2025 | |
| Ani Pharmaceuticals, INC. | $19.57 | 2025 | Purified Cortrophin Gel |
| Sandoz INC. | $18.53 | 2024 | Cimerli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Solinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.